<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686110</url>
  </required_header>
  <id_info>
    <org_study_id>2020-AO3395-34</org_study_id>
    <nct_id>NCT04686110</nct_id>
  </id_info>
  <brief_title>Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA</brief_title>
  <acronym>CAPISLA</acronym>
  <official_title>Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis, or Charcot's disease, is a neurodegenerative disease affecting&#xD;
      motor neurons. The disease affects between 5 and 10 people per 100,000 in the world, nearly&#xD;
      7,000 patients are affected in France. The only therapeutic treatment available to date in&#xD;
      France is riluzole, which slows the progression of the disease. Amyotrophic Lateral Sclerosis&#xD;
      is the first degenerative disease affecting motor neurons. However, recent evidence suggests&#xD;
      that the impairment extends beyond motor neurons alone.&#xD;
&#xD;
      Optical Coherence Tomography analyzes made it possible to highlight ophthalmologic damage in&#xD;
      patients with Amyotrophic Lateral Sclerosis, in particular at the macula and papilla,&#xD;
      although some results are contradictory.&#xD;
&#xD;
      No angiographic Optical Coherence Tomography analysis has been performed to date in patients&#xD;
      with Amyotrophic Lateral Sclerosis. However, in the hypothesis of microvascular involvement&#xD;
      participating in the pathophysiology of neurodegeneration in Amyotrophic Lateral Sclerosis,&#xD;
      these examinations could provide relevant clinical and pathophysiological data by studying&#xD;
      the retinal microvascularization of patients with the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the angiographic optical coherence tomography examination in patients with ALS in comparison with healthy controls</measure>
    <time_frame>at inclusion</time_frame>
    <description>Compare the angiographic optical coherence tomography examination in patients with ALS in comparison with healthy controls</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patients Amyotrophic Lateral Sclerosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>angiographic optical coherence tomography</intervention_name>
    <description>angiographic optical coherence tomography</description>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_label>Patients Amyotrophic Lateral Sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient Amyotrophic Lateral Sclerosis :&#xD;
&#xD;
          -  Patient diagnosed with bulbar or spinal ALS defined according to El Escorial criteria&#xD;
             (probable or certain)&#xD;
&#xD;
          -  Hospitalized in a day hospital at the Angers University Hospital as part of his usual&#xD;
             follow-up&#xD;
&#xD;
        Control subject :&#xD;
&#xD;
          -  Subject not affected by the disease studied and without a history of neurological&#xD;
             disease.&#xD;
&#xD;
          -  Subject matched in age and sex to a case (patient)&#xD;
&#xD;
        For all participants:&#xD;
&#xD;
          -  Major upon inclusion&#xD;
&#xD;
          -  Signature of informed consent to participate in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient Amyotrophic Lateral Sclerosis and control subject :&#xD;
&#xD;
          -  Simultaneous participation in another intervention protocol with an experimental&#xD;
             treatment&#xD;
&#xD;
          -  Subject unable to express consent&#xD;
&#xD;
          -  Known ophthalmologic pathology (maculopathy, glaucoma, optic neuropathy, retinopathy&#xD;
             whatever the etiology)&#xD;
&#xD;
          -  Diabetic subject&#xD;
&#xD;
          -  Cardiovascular history&#xD;
&#xD;
          -  Inability to perform the ophthalmological examinations of the study&#xD;
&#xD;
          -  Pregnant, lactating or parturient woman&#xD;
&#xD;
          -  Subject under duress psychiatric care&#xD;
&#xD;
          -  Subject to legal protection&#xD;
&#xD;
          -  Subject not affiliated or not beneficiary of a social security scheme&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Attach√©e de Recherche Clinique</last_name>
    <phone>0241353637</phone>
    <email>jeanne.muller@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Muller</last_name>
      <phone>0241353637</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

